Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Number of holders
-
204
-
Total 13F shares, excl. options
-
46,131,357
-
Shares change
-
+2,514,921
-
Total reported value, excl. options
-
$1,868,819,935
-
Value change
-
+$92,954,236
-
Put/Call ratio
-
0%
-
Number of buys
-
130
-
Number of sells
-
78
-
Price
-
$40.51
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q2 2025
As of 30 Jun 2025 Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) had 204 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 46,131,357 shares of stock of the company.
Largest 10 holders included BlackRock, Inc., RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, JENNISON ASSOCIATES LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, MORGAN STANLEY, JANUS HENDERSON GROUP PLC, Deep Track Capital, LP, and Frazier Life Sciences Management, L.P..
This table shows 204 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.